{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02016508",
      "OrgStudyIdInfo": {
        "OrgStudyId": "NCT 4619792013"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "4619792013",
            "SecondaryIdType": "Other Grant/Funding Number",
            "SecondaryIdDomain": "Al-Azhar university"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Al-Azhar University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Safety Study of Use of Autologous Bone Marrow Derived Stem Cell in Treatment of Age Related Macular Degeneration",
      "OfficialTitle": "Intravitreal Injection of Human Bone Marrow Derived Mesenchymal Stem Cell in Patients With Dry Age-related Macular Degeneration(AMD)"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2013",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2013"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "April 2015",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2015",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "May 18, 2013",
      "StudyFirstSubmitQCDate": "December 16, 2013",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 20, 2013",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "December 20, 2013",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 24, 2013",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "abdelhakim mohamed safwat",
        "ResponsiblePartyInvestigatorTitle": "assistant lecturer ophthalmology department al-azhar university",
        "ResponsiblePartyInvestigatorAffiliation": "Al-Azhar University"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Al-Azhar University",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Hassan , Hosny , M.D. M.Sc",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Samour , Hany M.D. M.Sc",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Ismail , Mahmoud M.D. M.Sc",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Higazy , Hasan M.D. M.Sc",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Abou el kheir, Wael, M.D. M.Sc.",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Gabr, Hala , M.D. M.Sc.",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Bakry, Sayed , phD. M.Sc.",
            "CollaboratorClass": "UNKNOWN"
          }
        ]
      }
    },
    "OversightModule": {},
    "DescriptionModule": {
      "BriefSummary": "The purpose of this Phase I/II study is to investigate the safety and preliminary efficacy of unilateral intravitreally transplantation of adult bone marrow stem cells in subjects with geographic atrophy secondary to age-related macular degeneration.",
      "DetailedDescription": "This study is an open-label investigation of the safety and preliminary efficacy of unilateral intravitreal injection of autologous bone marrow stem cells in subjects with Geographic Atrophy secondary to Age-Related Macular Degeneration (AMD). Subjects will be enrolled based on specific inclusion/exclusion criteria and evaluated at regular post transplant intervals.\n\nHuman central nervous system -stem cells will be transplanted by a vitreoretinal surgeon. The transplantation will be conducted in the eye with the inferior best-corrected visual acuity (BCVA) (i.e., the Study Eye). Only the Study Eye will undergo transplantation. The adult bone marrow stem cells will be administered into the vitreous cavity through a standard surgical approach.\n\nMoxifloxacin 300 mg(once per day ) will be administered orally to all subjects for a period of five days ( 2 days pre and post operatively) .\n\nSubjects will be monitored frequently for a total of one year after adult bone marrow stem cells cell injection ."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Age Related Macular Degeneration"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Adult bone marrow stem cells",
          "AMD"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "1",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "autologous bone marrow stem cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "use of autologous bone marrow derived stem cells as intravitreal injection in AMD patients",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: autologous bone marrow derived stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "autologous bone marrow derived stem cells",
            "InterventionDescription": "intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "autologous bone marrow stem cells"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "number of subjects with adverse events",
            "PrimaryOutcomeDescription": "Descriptive analysis of frequency and types of adverse events experienced by each subject during the study period",
            "PrimaryOutcomeTimeFrame": "6 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Assessment of visual function changes from the base line",
            "SecondaryOutcomeDescription": "assessment will include Change in the mean of BCVA, Optical Coherence Tomography imaging, fluorescein angiography, slitlamp examination with fundus photography, Electroretinographic evidence (mfERG) showing enhanced activity in the location",
            "SecondaryOutcomeTimeFrame": "6 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nDiagnosis of age-related macular degeneration with geographic atrophy (GA)\nOnly patients with a specific degree and extent of GA will be eligible\nSubjects with best-corrected visual acuity (BCVA) of less than or equal to 20/400 in the Study Eye\nNo prior or current choroidal neovascularization in either eye\nAble to provide written informed consent prior to any study related procedures\nAgree to comply in good faith with all conditions of the study and to attend all required study visits\n\nExclusion Criteria:\n\nPrior vitreal or retinal surgery in the previous 6 months\nGlaucoma\nAtrophic macular disease of any other cause\nDiabetic retinopathy or diabetic macular edema in either eye\nPrevious organ, tissue or bone marrow transplantation\nAutoimmune disease\nAllergy to moxifloxacin\nCurrent or prior malignancy (or is on chemotherapy)",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "50 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Abdelhakim mohamed safwat, M.D.",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+201005151919",
            "CentralContactEMail": "abdelhakimsafwat@gmail.com"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Al-Azhar university medical school (Benin-cairo) ophthalmology department",
            "LocationStatus": "Recruiting",
            "LocationCity": "Cairo",
            "LocationState": "Nasr city",
            "LocationCountry": "Egypt",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Abdelhakim Mohamed Safwat, Msc",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008268",
            "ConditionMeshTerm": "Macular Degeneration"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000012162",
            "ConditionAncestorTerm": "Retinal Degeneration"
          },
          {
            "ConditionAncestorId": "D000012164",
            "ConditionAncestorTerm": "Retinal Diseases"
          },
          {
            "ConditionAncestorId": "D000005128",
            "ConditionAncestorTerm": "Eye Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10412",
            "ConditionBrowseLeafName": "Macular Degeneration",
            "ConditionBrowseLeafAsFound": "Age-related Macular Degeneration",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14149",
            "ConditionBrowseLeafName": "Retinal Degeneration",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14151",
            "ConditionBrowseLeafName": "Retinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7423",
            "ConditionBrowseLeafName": "Eye Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC11",
            "ConditionBrowseBranchName": "Eye Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}